adamantane has been researched along with Alzheimer Disease in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Benedet, AL; Chakravarty, M; Chamoun, M; Cuello, AC; Dickerson, BC; DuBois, JM; Farzin, S; Gauthier, S; Gilbert, TM; Guiot, MC; Hightower, BG; Hooker, JM; Hopewell, R; Hwang, H; Hyman, BT; Kang, MS; Kobayashi, E; Lax, E; Lussier, FZ; Massarweh, G; Mathotaarachchi, S; Mohaddes, S; Ng, KP; Pascoal, TA; Rosa-Neto, P; Salaciak, A; Savard, M; Schroeder, FA; Shin, M; Soucy, JP; Szyf, M; Therriault, J; Thomas, E; Tullo, S; Wang, C; Wey, HY; Zürcher, NR | 1 |
| Alexandrova, A; Bibi, A; Dragomanova, S; Georgieva, A; Kalfin, R; Lazarova, M; Munkuev, A; Reynisson, J; Salakhutdinov, N; Stefanova, M; Suslov, E; Tancheva, L; Tzvetanova, E; Uzunova, D; Volcho, K | 1 |
| Baazaoui, N; Dai, CL; Iqbal, K; Liu, F; Liu, Y; Tung, YC; Wei, W | 1 |
| Baazaoui, N; Iqbal, K | 1 |
| Huang, M; Jiang, LF; Ma, QH; Mao, JL; Xu, WX | 1 |
| Bernhardt, PV; Braidy, N; Jansson, PJ; Kalinowski, DS; Palanimuthu, D; Richardson, DR; Wu, Z | 1 |
| Atrián-Blasco, E; Cerrada, E; Faller, P; Hureau, C; Laguna, M | 1 |
| Bachurin, SO; Boltneva, NP; Kovaleva, NV; Lushchekina, SV; Makhaeva, GF; Richardson, RJ; Rudakova, EV; Shevtsova, EF | 1 |
| Chen, S; Chen, Y; Deng, Y; Fernando, RL; Guo, A; Peng, P; Sun, J; Zhao, G; Zhou, M | 1 |
| Andrisano, V; Barniol-Xicota, M; Bartolini, M; De Simone, A; Espargaró, A; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Pivetta, D; Pont, C; Sabate, R; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
| Basavan, D; Chinni, S; Dubala, A; Gali, CC; Holsinger, RM; Khatwal, RB; Kosaraju, J; Madhunapantula, VS; Muthureddy Nataraj, SK | 1 |
| Basavan, D; Chinni, S; Dubala, A; Khatwal, RB; Kosaraju, J; Murthy, V; Muthureddy Nataraj, SK | 1 |
| Tundis, R; Xiao, J | 1 |
| Greco, N; Katz, DA; Lenz, RA; Liu, W; Marek, GJ; Meier, A; Zhang, W | 1 |
| Atrián-Blasco, E; Cerrada, E; Conte-Daban, A; Faller, P; Hureau, C; Laguna, M; Testemale, D | 1 |
| Bolognin, S; Chalbot, S; Iqbal, K; Khatoon, S; Puoliväli, J | 1 |
| Cho, CH; Cho, SW; Choi, SY; Kim, EA; Kim, J; Yang, SJ | 1 |
| Korabecny, J; Kuca, K; Nepovimova, E; Soukup, O; Spilovska, K; Windisch, M; Zemek, F | 1 |
| Adejare, A; Adeniji, AO; Wells, RM | 1 |
| Chen, HS; Eu, J; Gong, T; James, WL; Lipton, SA; Porter, S; Stamler, JS; Wang, Y; Washburn, M; Went, GT | 1 |
| Shah, RC | 1 |
| Lipton, SA | 1 |
3 review(s) available for adamantane and Alzheimer Disease
| Article | Year |
|---|---|
Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Binding Sites; Carbazoles; Carbolines; Cholinesterase Inhibitors; Cholinesterases; Humans; Molecular Docking Simulation; Phenothiazines | 2019 |
Adamantane - A Lead Structure for Drugs in Clinical Practice.
Topics: Adamantane; Alzheimer Disease; Antiviral Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Influenza, Human | 2016 |
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Topics: Adamantane; Alzheimer Disease; Animals; Dementia, Vascular; Humans; Memantine; Neuroprotective Agents; Nitric Acid; Receptors, N-Methyl-D-Aspartate | 2007 |
1 trial(s) available for adamantane and Alzheimer Disease
| Article | Year |
|---|---|
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.
Topics: Adamantane; Aged; Alzheimer Disease; Donepezil; Double-Blind Method; Female; Humans; Indans; Male; Neuropsychological Tests; Nootropic Agents; Piperazines; Piperidines; Treatment Outcome | 2014 |
18 other study(ies) available for adamantane and Alzheimer Disease
| Article | Year |
|---|---|
[
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognitive Dysfunction; Histone Deacetylase 1; Histone Deacetylases; Humans; Hydroxamic Acids; Positron-Emission Tomography; Rats; tau Proteins | 2022 |
New Myrtenal-Adamantane Conjugates Alleviate Alzheimer's-Type Dementia in Rat Model.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Animals; Antioxidants; Bicyclic Monoterpenes; Maze Learning; Neurodegenerative Diseases; Neuroprotective Agents; Norepinephrine; Oxidative Stress; Rats; Rats, Wistar; Scopolamine; Serotonin | 2022 |
Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction.
Topics: Adamantane; Alzheimer Disease; Animals; Cognition; Cognitive Dysfunction; Disease Models, Animal; Early Medical Intervention; Maze Learning; Mice; Mice, Transgenic; Nerve Growth Factors; Neuronal Plasticity; Oligopeptides; Postpartum Period; Signal Transduction; Treatment Outcome | 2021 |
Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound.
Topics: Adamantane; Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Cognition Disorders; Disease Models, Animal; Drug Administration Schedule; Female; Mice; Mice, Transgenic; Mutation; Neurodegenerative Diseases; Neuroprotective Agents; Oligopeptides; Presenilin-1; Recognition, Psychology; tau Proteins; Tauopathies | 2017 |
Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; bcl-2-Associated X Protein; Caspase 3; Cognitive Dysfunction; Disease Models, Animal; Disks Large Homolog 4 Protein; Gene Expression Regulation; Glycogen Synthase Kinase 3 beta; Hippocampus; Injections, Intraventricular; Male; Maze Learning; Neurons; Neuroprotective Agents; Nitriles; Nootropic Agents; Peptide Fragments; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats; Rats, Sprague-Dawley; Signal Transduction; Synaptophysin; tau Proteins; Vildagliptin | 2018 |
Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chelating Agents; Drug Screening Assays, Antitumor; Humans; Hydrazones; Models, Molecular; Molecular Structure; Organometallic Compounds; Oxidative Stress; Protein Aggregates; Semicarbazones | 2018 |
Role of PTA in the prevention of Cu(amyloid-β) induced ROS formation and amyloid-β oligomerisation in the presence of Zn.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Copper; Humans; Ligands; Organophosphorus Compounds; Protein Multimerization; Reactive Oxygen Species; Zinc | 2019 |
DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Cortex; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycosylation; Hippocampus; Humans; Intermediate Filaments; Learning; Memory Disorders; Mice; Mice, Transgenic; Nerve Degeneration; Phosphorylation; Signal Transduction; Sitagliptin Phosphate; tau Proteins | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tacrine | 2019 |
Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antibiotics, Antineoplastic; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Exploratory Behavior; Gene Expression Regulation; Glucagon-Like Peptide 1; Hippocampus; Interleukin-1beta; Male; Maze Learning; Rats; Rats, Wistar; Streptozocin; tau Proteins; Tumor Necrosis Factor-alpha | 2013 |
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hippocampus; Hypoglycemic Agents; Interleukin-1beta; Male; Maze Learning; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Streptozocin; tau Proteins; Tumor Necrosis Factor-alpha; Vildagliptin | 2013 |
Natural products for Alzheimer's disease therapy: basic and application.
Topics: Adamantane; Alzheimer Disease; Animals; Berberis; Biological Products; Cholinesterase Inhibitors; Drugs, Chinese Herbal; Humans; Nitriles; Phytotherapy; Pyrrolidines; Structure-Activity Relationship; Vildagliptin | 2013 |
Copper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Copper; Humans; Organophosphorus Compounds; Oxidation-Reduction; Reactive Oxygen Species | 2015 |
Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound.
Topics: Adamantane; Administration, Oral; Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biomarkers; Blotting, Western; Cerebral Cortex; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Hippocampus; Humans; Immunoblotting; Nootropic Agents; Oligopeptides; Rats, Inbred F344; Recombinant Proteins; tau Proteins; Treatment Outcome | 2015 |
N-Adamantyl-4-methylthiazol-2-amine suppresses amyloid β-induced neuronal oxidative damage in cortical neurons.
Topics: Adamantane; Alzheimer Disease; Amyloid beta-Peptides; Animals; Neurons; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Thiazoles | 2016 |
Syntheses and in-vitro evaluation of novel adamantane based γ-secretase inhibitors.
Topics: Adamantane; Alzheimer Disease; Amyloid Precursor Protein Secretases; Humans; Models, Molecular | 2012 |
The pharmacology of aminoadamantane nitrates.
Topics: Adamantane; Alzheimer Disease; Animals; Aorta; Drug Evaluation, Preclinical; In Vitro Techniques; Nitrates; Rabbits; Receptors, N-Methyl-D-Aspartate; Recombinant Proteins; Sodium Channels; Vasodilation | 2006 |
Shift shown in influenza A adamantane resistance.
Topics: Adamantane; Alzheimer Disease; Antiviral Agents; Drug Resistance, Viral; Excitatory Amino Acid Antagonists; Humans; Influenza A virus; Influenza, Human; Memantine | 2006 |